Last reviewed · How we verify
NCT04627077: LCI PROs
Livestrong Cancer Institutes' Patient Reported Outcomes Study
trial in Neoplasms in 121 participants. Completed in 25 January 2019.
25 January 2019
Quick facts
| Lead sponsor | University of Texas at Austin |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 121 |
| Start date | 22 January 2018 |
| Primary completion | 25 January 2019 |
| Estimated completion | 25 January 2019 |
| Sites | 1 location across United States |
Conditions studied
- Neoplasms — all drugs for Neoplasms →
- Drug Therapy — all drugs for Drug Therapy →
Sponsor
University of Texas at Austin
Who can join
18 and older, any sex, with Neoplasms or Drug Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study will be to collect baseline patient reported outcome measures at the Livestrong Cancer Institutes (LCI) with the goal of improving quality care and to inform decision making by patients, providers, and researchers for future LCI initiatives.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04627077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasms
Currently open trials in the same condition.
- NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
- NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
- NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting
Other University of Texas at Austin trials
Trials by the same sponsor.
- NCT07319234 — Development of MENU Protocol · NA · not yet recruiting
- NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) · NA · not yet recruiting
- NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children · NA · not yet recruiting
- NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi · NA · not yet recruiting
- NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04627077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
- Last refreshed: 13 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04627077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing